HB Portfolio is a financial services firm that generates revenue through trading in commodities and securities, managing an investment portfolio, and providing inter-corporate loans.
The company lacks a structural competitive advantage, as evidenced by extremely low average ROCE and ROE (approx. 1.5%) which are well below the cost of capital. Its performance is entirely dependent on broader market volatility and benchmark index movements rather than proprietary pricing power or cost advantages.
Management has focused on internal group investments and inter-corporate loans rather than returning significant value to shareholders. Recent allocation includes a 25 crore INR commitment to a hospitality subsidiary, which represents a pivot away from core financial operations into a capital-intensive sector with unproven returns.
The investment collapsed as the company's pivot into the capital-intensive hospitality sector drained liquidity without generating returns, while the core portfolio remained tethered to market volatility. Management's preference for inter-corporate loans and group-entity transactions over shareholder distributions eventually led to a stagnant book value. As the gap between the cost of capital and the meager 1.5% return on equity widened, the market finally de-rated the stock to a deep discount against its deteriorating assets.
RichFakir rates HB Portfolio Ltd's business quality as poor — 20/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, HB Portfolio Ltd is trading about 37% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on HB Portfolio Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of HB Portfolio Ltd's fair value is about ₹43 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →